Corvus Pharmaceuticals Dirección
Dirección controles de criterios 4/4
Corvus Pharmaceuticals' El consejero delegado es Rick Miller , nombrado en Feb 2014, tiene un mandato de 9.83 años. la remuneración anual total es $524.24K , compuesta por 57.2% salario y 42.8% primas, incluidas acciones y opciones de la empresa. posee directamente 3.04% de las acciones de la empresa, por valor de $2.40M . La antigüedad media del equipo directivo y del consejo de administración es de 6.5 años y 8 años respectivamente.
Información clave
Rick Miller
Chief Executive Officer (CEO)
US$524.2k
Compensación total
| Porcentaje del salario del CEO | 57.2% |
| Permanencia del CEO | 10.2yrs |
| Participación del CEO | 3.0% |
| Permanencia media de la dirección | 4.3yrs |
| Promedio de permanencia en la Junta Directiva | 8.9yrs |
Actualizaciones recientes de la dirección
Recent updates
Will Corvus Pharmaceuticals (NASDAQ:CRVS) Spend Its Cash Wisely?
Mar 06
Here's Why We're Watching Corvus Pharmaceuticals' (NASDAQ:CRVS) Cash Burn Situation
Oct 23Is Corvus Pharmaceuticals (NASDAQ:CRVS) In A Good Position To Invest In Growth?
May 16Here's Why We're Watching Corvus Pharmaceuticals' (NASDAQ:CRVS) Cash Burn Situation
Dec 05Corvus' partner Angel Pharma gets nod to start phase 1/1b trial of cancer therapy in China
Sep 26We're Keeping An Eye On Corvus Pharmaceuticals' (NASDAQ:CRVS) Cash Burn Rate
Aug 14Companies Like Corvus Pharmaceuticals (NASDAQ:CRVS) Are In A Position To Invest In Growth
Apr 05We're Hopeful That Corvus Pharmaceuticals (NASDAQ:CRVS) Will Use Its Cash Wisely
Dec 15Checking In On Corvus Pharmaceuticals
Dec 10Corvus: Surging On AstraZeneca CD73 Success With Key Data Readout Looming
Sep 22We Think Corvus Pharmaceuticals (NASDAQ:CRVS) Can Afford To Drive Business Growth
Aug 26Corvus Pharmaceuticals initiated buy at Cantor with a Street-high target
May 27Is Corvus Pharmaceuticals (NASDAQ:CRVS) In A Good Position To Deliver On Growth Plans?
May 08The Co-Founder of Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), Richard Miller, Just Bought 8.5% More Shares
Feb 19Here's Why We're Watching Corvus Pharmaceuticals' (NASDAQ:CRVS) Cash Burn Situation
Feb 07Here's What Corvus Pharmaceuticals, Inc.'s (NASDAQ:CRVS) Shareholder Ownership Structure Looks Like
Dec 16Corvus Pharmaceuticals EPS misses by $0.06
Oct 29Análisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Dec 31 2023 | n/a | n/a | -US$27m |
| Sep 30 2023 | n/a | n/a | -US$30m |
| Jun 30 2023 | n/a | n/a | -US$39m |
| Mar 31 2023 | n/a | n/a | -US$41m |
| Dec 31 2022 | US$524k | US$300k | -US$41m |
| Sep 30 2022 | n/a | n/a | -US$41m |
| Jun 30 2022 | n/a | n/a | -US$37m |
| Mar 31 2022 | n/a | n/a | -US$40m |
| Dec 31 2021 | US$905k | US$300k | -US$43m |
| Sep 30 2021 | n/a | n/a | -US$7m |
| Jun 30 2021 | n/a | n/a | -US$6m |
| Mar 31 2021 | n/a | n/a | -US$5m |
| Dec 31 2020 | US$1m | US$300k | -US$6m |
| Sep 30 2020 | n/a | n/a | -US$44m |
| Jun 30 2020 | n/a | n/a | -US$46m |
| Mar 31 2020 | n/a | n/a | -US$48m |
| Dec 31 2019 | US$1m | US$300k | -US$47m |
| Sep 30 2019 | n/a | n/a | -US$46m |
| Jun 30 2019 | n/a | n/a | -US$46m |
| Mar 31 2019 | n/a | n/a | -US$44m |
| Dec 31 2018 | US$1m | US$300k | -US$47m |
| Sep 30 2018 | n/a | n/a | -US$48m |
| Jun 30 2018 | n/a | n/a | -US$51m |
| Mar 31 2018 | n/a | n/a | -US$54m |
| Dec 31 2017 | US$1m | US$302k | -US$56m |
Compensación vs. Mercado: La compensación total de Rick ($USD524.24K) es aproximadamente el promedio para empresas de tamaño similar en el mercado US ($USD738.70K).
Compensación vs. Ingresos: La compensación de Rick ha sido consistente con los resultados de la empresa en el último año.
CEO
Rick Miller (72 yo)
10.2yrs
Permanencia
US$524,239
Compensación
Dr. Richard A. Miller, also known as Rick, M.D., serves as Director of BrainScope Company Inc. since September 2023. He is a Co-Founder of Corvus Pharmaceuticals, Inc. and has been its Chief Executive Offi...
Equipo directivo
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| Co-Founder | 10.2yrs | US$524.24k | 3.04% $ 2.1m | |
| Co-Founder & Independent Director | no data | US$67.80k | 0% $ 0 | |
| Chief Financial Officer | 9.4yrs | US$497.85k | 0.58% $ 395.4k | |
| Senior Vice President of Pharmaceutical Development | 4.3yrs | US$455.54k | 0.27% $ 187.3k | |
| Senior Vice President of Research | 1.8yrs | sin datos | sin datos | |
| Chief Business Officer | less than a year | sin datos | sin datos |
4.3yrs
Permanencia media
66yo
Promedio de edad
Equipo directivo experimentado: CRVSEl equipo directivo de la empresa se considera experimentado (4.2 años de antigüedad media).
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| Co-Founder | 10.3yrs | US$524.24k | 3.04% $ 2.1m | |
| Co-Founder & Independent Director | 9.4yrs | US$67.80k | 0% $ 0 | |
| Independent Director | 9.4yrs | US$73.80k | 0% $ 0 | |
| Independent Director | 5.3yrs | US$69.80k | 0.020% $ 14.0k | |
| Independent Director | 7.3yrs | US$65.80k | 0% $ 0 | |
| Independent Director | 8.3yrs | US$81.80k | 0% $ 0 |
8.9yrs
Permanencia media
65.5yo
Promedio de edad
Junta con experiencia: La junta directiva de CRVS se considera experimentada (8 años de antigüedad promedio).